AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1-15. (canceled)

16. (previously presented) A method of treating a mutant p53 mediated disease, comprising administrating to a mammal in need thereof a pharmaceutically efficient amount of a compound selected from compounds having a structure according to the formula I

wherein:

R1 is hydrogen or a methylene group, which can be double bonded, as indicated by the broken line, or single bonded and linked to the nitrogen atom of an amine-substituted phenyl group, to a nitrogen atom contained in the ring structure of a purine, 8-azapurine, or benzimidazol residue, and;

A is an oxygen-containing moiety, either consisting of an oxygen atom being double bonded, as indicated

Docket No. 1505-1052 Appln. No. 10/505,407

by the broken line, or a benzoyloxy group, with the proviso that when A is a benzoyloxy group, then R1 is hydrogen.

- 17. (currently amended) The method of claim [[7]] $\underline{16}$, wherein the mutant p53 mediated disease is cancer.
- 18. (new) The method of claim 16, wherein the compound is combined with a pharmaceutically acceptable carrier, diluent and/or excipient.